Current Status, Opportunities, Applications, and Challenges of RNA Interference-Based Cancer Therapeutics

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F25%3A43921629" target="_blank" >RIV/00023752:_____/25:43921629 - isvavai.cz</a>

Výsledek na webu

<a href="https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/slct.202504048" target="_blank" >https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/slct.202504048</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/slct.202504048" target="_blank" >10.1002/slct.202504048</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Current Status, Opportunities, Applications, and Challenges of RNA Interference-Based Cancer Therapeutics

Popis výsledku v původním jazyce

Cancer is one of the leading causes of death globally, where the development of effective therapies is critical. Traditional cancer treatment methods, such as chemotherapy and radiation, often lead to several side effects in patients due to their systemic toxicity and the emergence of drug resistance. Thus, there is a quest for an alternative approach for less/nontoxic cancer treatment modalities. One of the most fascinating and practical biological discoveries in recent years is the phenomenon of RNA interference (RNAi), which serves as a regulator of gene expression. Across the spectrum of organisms, suppressing gene expression can be swiftly and effectively accomplished using double-stranded RNA-mediated interference. Hence, RNAi is proposed as a potential cancer treatment alternative by enabling targeted silencing of genes, which can disrupt the expression of oncogenes and restore the function of tumor suppressor genes. However, the successful implementation of RNAi requires efficient delivery systems that can play a vital role in overcoming the barriers associated with stability and cellular uptake. Thus, this review aims to discuss the abilities of RNA interference in cancer therapy, examining its challenges and its future perspectives.

Název v anglickém jazyce

Current Status, Opportunities, Applications, and Challenges of RNA Interference-Based Cancer Therapeutics

Popis výsledku anglicky

Cancer is one of the leading causes of death globally, where the development of effective therapies is critical. Traditional cancer treatment methods, such as chemotherapy and radiation, often lead to several side effects in patients due to their systemic toxicity and the emergence of drug resistance. Thus, there is a quest for an alternative approach for less/nontoxic cancer treatment modalities. One of the most fascinating and practical biological discoveries in recent years is the phenomenon of RNA interference (RNAi), which serves as a regulator of gene expression. Across the spectrum of organisms, suppressing gene expression can be swiftly and effectively accomplished using double-stranded RNA-mediated interference. Hence, RNAi is proposed as a potential cancer treatment alternative by enabling targeted silencing of genes, which can disrupt the expression of oncogenes and restore the function of tumor suppressor genes. However, the successful implementation of RNAi requires efficient delivery systems that can play a vital role in overcoming the barriers associated with stability and cellular uptake. Thus, this review aims to discuss the abilities of RNA interference in cancer therapy, examining its challenges and its future perspectives.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10406 - Analytical chemistry

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ChemistrySelect

ISSN

2365-6549

e-ISSN

2365-6549

Svazek periodika

10

Číslo periodika v rámci svazku

46

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

24

Strana od-do

"e04048"

Kód UT WoS článku

001630395300001

EID výsledku v databázi Scopus

2-s2.0-105023870020